Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mutation rate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,106 result(s) found for: Mutation rate. Displaying page 1 of 56.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-003411-34 Sponsor Protocol Number: 1200.264 Start Date*: 2017-06-21
    Sponsor Name:BSMO
    Full Title: Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation.
    Medical condition: cancers harbouring an EGFR mutation (excluding non-squamous non- small cell lung cancer, a registered indication), a HER2 mutation or a HER3 mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002966-37 Sponsor Protocol Number: 1-2018BSMO Start Date*: 2019-01-23
    Sponsor Name:Belgian Society of Medical Oncology
    Full Title: Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes.
    Medical condition: Advanced cancer patients that have a germline mutation or a somatic mutation in their tumor. Prostate and ovarian cancer patients and breast cancer patients who carry a BRCA1/2 mutation will be exc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002637-11 Sponsor Protocol Number: CBYL719H12301 Start Date*: 2020-03-18
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with adv...
    Medical condition: Advanced triple negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) SK (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) NO (Completed) AT (Completed) BG (Completed) SI (Completed) PL (Completed) HR (Completed) GR (Completed) RO (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001731-20 Sponsor Protocol Number: ML29741 Start Date*: 2016-03-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A SINGLE ARM, OPEN LABEL, PHASE II, MULTICENTER STUDY TO ASSESS THE DETECTION OF THE BRAF V600 MUTATION ON cfDNA FROM PLASMA IN PATIENTS WITH ADVANCED MELANOMA
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001696-79 Sponsor Protocol Number: KH176-201 Start Date*: 2016-09-06
    Sponsor Name:Khondrion BV
    Full Title: A double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitoc...
    Medical condition: Inherited mitochondrial disease, including MELAS (mitochondrial Encephalopathy Lactic Acidosis and Stroke like episodes) and MIDD (Maternally Inherited Diabetes and Deafness)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023526-21 Sponsor Protocol Number: MO25515 Start Date*: 2011-03-14
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Estudio multicéntrico, abierto, de acceso expandido, de RO5185426 en pacientes con melanoma metastásico An open-label, multicenter expanded access study of RO5185426 in patients with metastatic me...
    Medical condition: Tratamiento de pacientes adultos con melanoma metastásico confirmado histológicamente, portador de la mutación BRAF V600 identificada por medio del test Cobas 4800 para mutaciones BRAF V600, en los...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) SE (Completed) NL (Completed) SI (Completed) GR (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed) SK (Completed) BE (Completed) BG (Completed) NO (Completed) PT (Completed) LV (Completed) FI (Completed) IT (Completed) DK (Completed) EE (Completed) LT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000423-14 Sponsor Protocol Number: D1532C00065 Start Date*: 2013-05-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Diff...
    Medical condition: Differentiated Thyroid Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Completed) FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-004683-30 Sponsor Protocol Number: KRAS2011 Start Date*: 2012-05-02
    Sponsor Name:VU University Medical
    Full Title: A phase II study of sorafenib and metformin in patients with locally advanced and/or metastatic non-smal cell lung cancer (NSCLC) with a K-Ras mutation
    Medical condition: Patients with advanced non small cell lung cancer that harbours a K-Ras mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002238-29 Sponsor Protocol Number: NL49479.029.14 Start Date*: 2014-12-18
    Sponsor Name:
    Full Title: Paclitaxel-trastuzumab in EGFR-mutated NSCLC patients after progression on TKI-treatment; a pilot study
    Medical condition: NSCLC with EGFR mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000266-35 Sponsor Protocol Number: CTKI258A2211 Start Date*: 2012-03-21
    Sponsor Name:NOVARTIS FARMA
    Full Title: A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and...
    Medical condition: Advanced and/or metastatic endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022838-85 Sponsor Protocol Number: MEK114267 Start Date*: 2010-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: MEK114267, A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma
    Medical condition: Advanced or metastatic BRAF V600E/K mutation-positive melanoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed) CZ (Completed) GR (Completed) NO (Completed) GB (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003128-11 Sponsor Protocol Number: CA180-385 Start Date*: 2012-05-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutation Pharmacogenetics Blood Amendment 1; Revised Protocol 02 incorporating amendm...
    Medical condition: Carcinoma, Non-small cell lung
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10007284 Carcinoma LLT
    14.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005492-12 Sponsor Protocol Number: BDTX-189-01 Start Date*: 2021-05-27
    Sponsor Name:Black Diamond Therapeutics, Inc.
    Full Title: MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutation...
    Medical condition: NSCLC, breast cancer, biliary tract cancer, or cervical cancer, any other solid tumors with specific gene mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) ES (Completed) IT (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000280-84 Sponsor Protocol Number: ML28882 Start Date*: 2013-08-15
    Sponsor Name:Finnish melanoma group
    Full Title: COBRA: TOL+ INTERFERON-alpha COMBINED WITH VEMURAFENIB (BRAF-mutation positive patients) OR TOL + INTERFERON- alpha (BRAF-mutation negative patients) FOR PATIENTS WITH ADVANCED MELANOMA AS 1st CHEM...
    Medical condition: Patients with histologically confirmed metastatic melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005936-31 Sponsor Protocol Number: SMX18-001 Start Date*: 2021-05-24
    Sponsor Name:Sermonix Pharmaceuticals
    Full Title: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic E...
    Medical condition: Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001088-29 Sponsor Protocol Number: CJDQ443B12201 Start Date*: 2022-10-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-sm...
    Medical condition: locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) BG (Completed) NL (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014263-40 Sponsor Protocol Number: MEL01 Start Date*: 2009-12-14
    Sponsor Name:Penwest Pharmaceuticals Co.
    Full Title: A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 day, Two-arm, Parallel Group Study of A0001 in Patients with the A3243G Mitochondrial DNA Point Mutation and Evidence of Impaired Mitoch...
    Medical condition: A3243G mitochondrial DNA point mutation and evidence of impaired mitochondrial function
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004415-39 Sponsor Protocol Number: TO-TAS0728-101 Start Date*: 2019-02-05
    Sponsor Name:Taiho Oncology, Inc.
    Full Title: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAS0728, AN ORAL COVALENT BINDING INHIBITOR OF HER2, IN SUBJECTS WITH ADVANCED SOLID TUMORS W...
    Medical condition: Urothelial cancer with HER2 or HER3 mutation Biliary tract cancer with HER2 or HER3 mutation Breast cancer with HER2 or HER3 mutation Breast cancer with HER2 amplification/overexpression as per AS...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004593 Bile duct cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077840 Urothelial cancer of renal pelvis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005595-28 Sponsor Protocol Number: AIO-TRK-0214 Start Date*: 2015-09-29
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial.
    Medical condition: Patients with stage II, IIIA and IIIB non-squamous non-small-cell lung cancer with activating EGFR mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10073254 Neoadjuvant therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002432-17 Sponsor Protocol Number: ALN-AS1-003 Start Date*: 2017-11-22
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ENVISION: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porph...
    Medical condition: Acute Hepatic Porphyrias (AHP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036182 Porphyria acute PT
    20.0 10010331 - Congenital, familial and genetic disorders 10036184 Porphyria hepatic LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) DK (Completed) CZ (Completed) SE (Completed) BG (Completed) FI (Completed) BE (Completed) FR (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 20:44:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA